IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma
Gong, Jifang1; Hu, Bing2; Zhang, Xiaotian1; Zhang, Fengchun3; Zhang, Jun4; Xu, Nong e5; Fan, Qingxia6; Bai, Yuxian7; Jiao, Shunchang8; Wang, Jinwan9; Bai, Chunmei10; Zheng, Leizhen11; Shi, Yingqiang12; Liu, Yunpeng13; Liang, Jun14; Hu, Guoqing15; Cheng, Ying16; Xu, Ruihua17; Bai, Yu18; Shen, Lin1
刊名ONCOLOGIST
2014-02-01
DOI10.1634/theoncologist.2013-0137
19期:2页:173-174
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者National Natural Science Foundation of China ; National High Technology Research and Development Program ; Beijing Municipal Science &amp ; Technology Commission Program ; National Natural Science Foundation of China ; National High Technology Research and Development Program ; Beijing Municipal Science &amp ; Technology Commission Program
研究领域[WOS]Oncology
英文摘要

Background. The efficacy and toxicity of paclitaxel plus capecitabine (PX) as first-line treatment in advanced gastric cancer (AGC) was evaluated.

Methods. Patients with previously untreated AGC were included. PX was given every 3 weeks until a maximum of six cycles or progression. Capecitabine monotherapy was continued for patients without disease progression. The primary endpoint was progression-free survival, and secondary endpoints were objective response rate, overall survival (OS), and safety.

Results. Overall, 194 patients were treated per protocol and one patient was excluded because of allergy to paclitaxel. Response was evaluated in 175 patients, with an objective response rate of 34.8%. After a median follow-up of 33.2 months, disease progression was observed in 141 patients, 137 died, and 16 were lost to follow-up, with progression-free survival of 188 days and OS of 354 days. In multivariate Cox regression analysis, no factor remained an independent predictor of OS. Forty-five patients who received capecitabine monotherapy after PX had longer OS (531 days). Adverse events were mild (Fig. 1), and the most common grade 3-4 toxicities were leucopenia and neutropenia.

Conclusion. PX as a first-line treatment has promising efficacy in AGC. Based on these data, a phase III study has been launched for further investigation.

语种英语
所属项目编号81172110 ; 2006AA 02A 402-B02 ; 2012AA 02A 504 ; Z11110706730000
资助者National Natural Science Foundation of China ; National High Technology Research and Development Program ; Beijing Municipal Science &amp ; Technology Commission Program ; National Natural Science Foundation of China ; National High Technology Research and Development Program ; Beijing Municipal Science &amp ; Technology Commission Program
WOS记录号WOS:000332077300008
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61355
专题北京大学第一临床医学院
作者单位1.Peking Univ, Canc Hosp & Inst, Beijing 100142, Peoples R China
2.Anhui Prov Hosp, Hefei, Peoples R China
3.Suzhou Kowloon Hosp, Suzhou, Peoples R China
4.Ruijin Hosp, Shanghai, Peoples R China
5.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
6.Zhengzhou Univ, Affiliated Hosp 1, Henan, Peoples R China
7.Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
8.Chinese Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
9.Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100730, Peoples R China
10.Beijing Union Med Coll Hosp, Beijing, Peoples R China
11.Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China
12.Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
13.China Med Univ, Hosp 1, Shenyang, Peoples R China
14.Qingdao Univ, Coll Med, Affiliated Hosp, Qingdao 266071, Peoples R China
15.Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
16.Jilin Prov Tumor Hosp, Changchun, Peoples R China
17.Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
18.Peking Univ, Hosp 1, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Gong, Jifang,Hu, Bing,Zhang, Xiaotian,et al. The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma[J]. ONCOLOGIST,2014,19(2):173-174.
APA Gong, Jifang.,Hu, Bing.,Zhang, Xiaotian.,Zhang, Fengchun.,Zhang, Jun.,...&Shen, Lin.(2014).The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma.ONCOLOGIST,19(2),173-174.
MLA Gong, Jifang,et al."The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma".ONCOLOGIST 19.2(2014):173-174.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Gong, Jifang]的文章
[Hu, Bing]的文章
[Zhang, Xiaotian]的文章
百度学术
百度学术中相似的文章
[Gong, Jifang]的文章
[Hu, Bing]的文章
[Zhang, Xiaotian]的文章
必应学术
必应学术中相似的文章
[Gong, Jifang]的文章
[Hu, Bing]的文章
[Zhang, Xiaotian]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。